← Search & browse all drugs

paclitaxel and encequidar

L01CD51

Forms & Strengths

Oral tablet: paclitaxel 20 mg combined with encequidar 15 mg

Adult Dosing

Metastatic breast cancer: 205 mg paclitaxel / 15 mg encequidar orally once daily on Days 1, 8, and 15 of a 28-day cycle
Administer on an empty stomach (fast for 4 hours before and 2 hours after administration)
Premedicate with an antiemetic as appropriate

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established

Indications

Treatment of metastatic breast cancer

Mechanism of Action

Paclitaxel is a taxane that stabilizes microtubules, inhibits depolymerization, and arrests cell division
Encequidar is a potent P-glycoprotein inhibitor co-administered to enhance the intestinal absorption and oral bioavailability of paclitaxel

Contraindications

Baseline neutrophil count < 1,500 cells/mm3
Severe hepatic impairment
Known hypersensitivity to paclitaxel, encequidar, or Cremophor EL (if applicable formulation context)

Adverse Reactions

Neutropenia, leukopenia, anemia, thrombocytopenia
Peripheral neuropathy
Nausea, vomiting, diarrhea, abdominal pain
Fatigue, asthenia
Alopecia
Musculoskeletal pain, arthralgia, myalgia

Drug Interactions

Avoid strong CYP2C8 and CYP3A4 inhibitors and inducers, as paclitaxel is metabolized by these enzymes
Avoid strong P-glycoprotein inhibitors or inducers that may unpredictably alter encequidar or paclitaxel absorption
Use caution with medications known to prolong the QT interval or cause myelosuppression

Curated Content: Needs Vetting Before Put to Clinical Use